Nanocarry Therapeutics ⚠ Under review

About

Offices

Q&A

What is Nanocarry Therapeutics' primary focus?

Nanocarry Therapeutics is developing nanoparticle-based therapeutics for brain cancer and central nervous system (CNS) disorders. Their AxS platform is designed to deliver biologics to the brain and other areas.

When was Nanocarry Therapeutics founded?

Nanocarry Therapeutics was founded in January 2021.

How many employees does Nanocarry Therapeutics have?

Nanocarry Therapeutics has 11-50 employees.

What was Nanocarry Therapeutics' most recent funding round?

Nanocarry Therapeutics completed a Seed funding round in January 2025, with NFX Capital as a lead investor.

Which investors participated in Nanocarry Therapeutics' August 2024 funding round?

Sapir Venture Partners participated in Nanocarry Therapeutics' funding round in August 2024.

What grant funding did Nanocarry Therapeutics receive in January 2024?

In January 2024, Nanocarry Therapeutics received a grant of $1,000,000 from the Israel Innovation Authority.

Who are the co-founders of Nanocarry Therapeutics?

The co-founders of Nanocarry Therapeutics are Revital Mandil Levin (Co-founder & CEO), Rachela Popovtzer (Co-founder & CSO), and Oshra Betzer (Co-founder & CTO).

What types of cancer are Nanocarry Therapeutics' first products in development targeting?

Nanocarry Therapeutics' first products in development are for brain metastases of HER2+ breast cancer and non-small cell lung cancer.

Team · 9

Revital Mandil-Levin

Founder · CEO & Co-founder

Oshra Betzer

Founder · COO & Co-founder

Rachela Popovtzer

Founder · CSO & Co-founder

Michal Roytman

CBO

Ayelet Zafran

VP R&D

Konstantin Rozenberg

Senior Scientist

Sivan Shahar

Research Scientist

Barel Ohanuna

Research Scientist

Ella Abramovich

Research Assistant

Sectors & technology

Tags